Acrivon Therapeutics, Inc. (ACRV)
2.09
+0.03
(+1.46%)
USD |
NASDAQ |
Aug 31, 16:00
2.05
-0.04
(-1.91%)
After-Hours: 20:00
Acrivon Therapeutics Enterprise Value : 1.707M for Aug. 31, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 31, 2026 | 1.707M |
| August 28, 2026 | 0.4212M |
| August 27, 2026 | 4.278M |
| August 26, 2026 | 1.278M |
| August 25, 2026 | 5.563M |
| August 24, 2026 | 6.420M |
| August 21, 2026 | 6.848M |
| August 20, 2026 | 6.420M |
| August 19, 2026 | 14.56M |
| August 18, 2026 | -0.0072M |
| August 17, 2026 | -0.0072M |
| August 14, 2026 | -4.292M |
| August 13, 2026 | -8.577M |
| August 12, 2026 | -14.15M |
| August 11, 2026 | -13.72M |
| August 10, 2026 | -13.29M |
| August 07, 2026 | -13.72M |
| August 06, 2026 | -15.43M |
| August 05, 2026 | -17.57M |
| August 04, 2026 | -21.00M |
| August 03, 2026 | -21.00M |
| July 31, 2026 | -23.57M |
| July 30, 2026 | -22.72M |
| July 29, 2026 | -26.57M |
| July 28, 2026 | -21.86M |
| Date | Value |
|---|---|
| July 27, 2026 | -21.00M |
| July 24, 2026 | -19.29M |
| July 23, 2026 | -16.29M |
| July 22, 2026 | -15.86M |
| July 21, 2026 | -12.86M |
| July 20, 2026 | -13.29M |
| July 17, 2026 | -12.86M |
| July 16, 2026 | -12.86M |
| July 15, 2026 | -5.577M |
| July 14, 2026 | 3.420M |
| July 13, 2026 | -3.006M |
| July 10, 2026 | -3.864M |
| July 09, 2026 | -0.0072M |
| July 08, 2026 | -0.4357M |
| July 07, 2026 | -8.148M |
| July 06, 2026 | -11.58M |
| July 02, 2026 | -14.15M |
| July 01, 2026 | -13.72M |
| June 30, 2026 | -11.58M |
| June 29, 2026 | -26.36M |
| June 26, 2026 | -30.23M |
| June 25, 2026 | -34.10M |
| June 24, 2026 | -32.56M |
| June 23, 2026 | -32.17M |
| June 22, 2026 | -34.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.094B |
| Alnylam Pharmaceuticals, Inc. | 31.87B |
| Anika Therapeutics, Inc. | 266.14M |
| Savara, Inc. | 964.48M |
| Vericel Corp. | 1.974B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.96M |
| Total Expenses (Quarterly) | 17.96M |
| EPS Diluted (Quarterly) | -0.4293 |
| Earnings Yield | -90.19% |
| Normalized Earnings Yield | -90.19 |